Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC

Journal of the National Cancer Institute

Volumn 109, Issue 9, 2017, Pages

  Chaib, Imane ^a   Karachaliou, Niki ^b   Pilotto, Sara ^c   Codony Servat, Jordi ^b   Cai, Xueting ^d,e   Li, Xuefei ^f   Drozdowskyj, Ana ^g   Servat, Carles Codony ^b   Yang, Jie ^d,e   Hu, Chunping ^d,e   Cardona, Andres Felipe ^h   Vivanco, Guillermo Lopez ⁱ   Vergnenegre, Alain ^j   Sanchez, Jose Miguel ^k   Provencio, Mariano ^l   de Marinis, Filippo ^m   Passaro, Antonio ^m   Carcereny, Enric ⁿ   Reguart, Noemi ^o,p   Campelo, Charo Garcia ^q   Teixido, Cristina ^b   Sperduti, Isabella ^r   Rodriguez, Sonia ^b   Lazzari, Chiara ^m   Verlicchi, Alberto ^s   de Aguirre, Itziar ^a   Queralt, Cristina ^a   Wei, Jia ^t   Estrada, Roger ^u   de la Bellacasa, Raimon Puig ^u   Ramirez, Jose Luis ^a   Jacobsen, Kirstine ^v   Ditzel, Henrik J ^v,w   Santarpia, Mariacarmela ^x   Viteri, Santiago ^b   Molina, Miguel Angel ^b   Zhou, Caicun ^f   Cao, Peng ^d,e   Ma, Patrick C ^y,z   Bivona, Trever G ^aa   Rosell, Rafael ^a,b,n   more..

^a IrsiCaixa Aids Research Institute   (Spain)

^b INSTITUT UNIVERSITARI DEXEUS   (Spain)

^c UNIVERSITY HOSPITAL OF VERONA   (Italy)

^d NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

^e INSTITUTE OF CHINESE MATERIA MEDICA   (China)

^f TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^g PIVOTAL   (Spain)

^h Brain Tumor Section   (Colombia)

ⁱ HOSPITAL DE CRUCES   (Spain)

^j LIMOGES UNIVERSITY HOSPITAL   (France)

^k HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^l HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^m EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

ⁿ HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^o HOSPITAL CLÍNIC   (Spain)

^p INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^q Hospital A Coruna   (Spain)

^r REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^s SANTA MARIA DELLE CROCI HOSPITAL   (Italy)

^t THE AFFILIATED DRUM TOWER HOSPITAL OF NANJING UNIVERSITY MEDICAL SCHOOL   (China)

^u UNIVERSITAT RAMON LLULL   (Spain)

^v UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^w ODENSE UNIVERSITY HOSPITAL   (Denmark)

^x UNIVERSITY OF MESSINA   (Italy)

^y WEST VIRGINIA UNIVERSITY   (United States)

^z West Virginia Clinical and Translational Science Institute   (United States)

^aa UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

2 [(AMINOCARBONYL)AMINO] 5 (4 FLUOROPHENYL) 3 THIOPNENCARBOXAMIDE; AFATINIB; AMIDE; BETA ACTIN; CONNECTIVE TISSUE GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; ICOTINIB; INTERLEUKIN 6; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; OSIMERTINIB; PAXILLIN; PROTEIN KINASE B; RANTES; SARACATINIB; STAT3 PROTEIN; TRANSCRIPTION FACTOR YAP1; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; PHOSPHOPROTEIN; PROTEIN KINASE INHIBITOR; SIGNAL TRANSDUCING ADAPTOR PROTEIN; STAT3 PROTEIN, HUMAN; YAP1 (YES-ASSOCIATED) PROTEIN, HUMAN;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER REGRESSION; CANCER SIZE; CANCER SURVIVAL; CELL SURVIVAL; CELL VIABILITY; CLINICAL OUTCOME; CLONOGENIC ASSAY; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFICACY; ENZYME PHOSPHORYLATION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; MOUSE; NON SMALL CELL LUNG CANCER; NONHUMAN; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RETROSPECTIVE STUDY; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; ADENOCARCINOMA; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; GENETICS; LUNG NEOPLASMS; METABOLISM; MIDDLE AGED; NUDE MOUSE; TUMOR CELL LINE; VERY ELDERLY;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MICE; MICE, NUDE; MIDDLE AGED; PHOSPHOPROTEINS; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; RNA, MESSENGER; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR;

EID: 85017265055     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djx014     Document Type: Article

References (23)

1. Rosell R, Moran T, Queralt C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med. 2009;361(10):958-967.
2. Guo A, Villen J, Kornhauser J, et al. Signaling networks assembled by oncogenic EGFR and c-Met. Proc Natl Acad Sci U S A. 2008;105(2):692-697.
3. Phuchareon J, McCormick F, Eisele DW, et al. EGFR inhibition evokes innate drug resistance in lung cancer cells by preventing Akt activity and thus inactivating Ets-1 function. Proc Natl Acad Sci U S A. 2015;112(29): E3855-E3863.
4. Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13(3):239-246.
5. Sordella R, Bell DW, Haber DA, et al. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science. 2004;305(5687): 1163-1167.
6. Lazzara MJ, Lane K, Chan R, et al. Impaired SHP2-mediated extracellular signal-regulated kinase activation contributes to gefitinib sensitivity of lung cancer cells with epidermal growth factor receptor-activating mutations. Cancer Res. 2010;70(9):3843-3850.
7. Fan W, Tang Z, Yin L, et al. MET-independent lung cancer cells evading EGFR kinase inhibitors are therapeutically susceptible to BH3 mimetic agents. Cancer Res. 2011;71(13):4494-4505.
8. Lee HJ, Zhuang G, Cao Y, et al. Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells. Cancer Cell. 2014;26(2):207-221.
9. Zhong Z, Wen Z, Darnell JE Jr. Stat3: A STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6 Science. 1994;264(5155):95-98.
10. Blakely CM, Pazarentzos E, Olivas V, et al. NF-kappaB-activating complex engaged in response to EGFR oncogene inhibition drives tumor cell survival and residual disease in lung cancer. Cell Rep. 2015;11(1):98-110.
11. Bivona TG, Hieronymus H, Parker J, et al. FAS and NF-kappaB signalling modulate dependence of lung cancers on mutant EGFR. Nature. 2011;471(7339): 523-526.
12. Taniguchi K, Wu LW, Grivennikov SI, et al. A gp130-Src-YAP module links inflammation to epithelial regeneration. Nature. 2015;519(7541): 57-62.
13. Rosell R, Bivona TG, Karachaliou N. Genetics and biomarkers in personalisation of lung cancer treatment. Lancet. 2013;382(9893):720-731.
14. Lin L, Sabnis AJ, Chan E, et al. The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies. Nat Genet. 2015;47(3):250-256.
15. Podolin PL, Callahan JF, Bolognese BJ, et al. Attenuation of murine collageninduced arthritis by a novel, potent, selective small molecule inhibitor of IkappaB Kinase 2, TPCA-1 (2-[(aminocarbonyl)amino]-5-(4-fluorophenyl)-3-thiophenecarboxamide), occurs via reduction of proinflammatory cytokines and antigen-induced T cell Proliferation. J Pharmacol Exp Ther. 2005;312(1): 373-381.
16. Nan J, Du Y, Chen X, et al. TPCA-1 is a direct dual inhibitor of STAT3 and NFkappaB and regresses mutant EGFR-associated human non-small cell lung cancers. Mol Cancer Ther. 2014;13(3):617-629.
17. Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010;70(2):440-446.
18. Rosell R, Molina MA, Costa C, et al. Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations. Clin Cancer Res. 2011;17(5):1160-1168.
19. Yang J, Stark GR. Roles of unphosphorylated STATs in signaling. Cell Res. 2008;18(4):443-451.
20. Gönen M. Receiver operating characteristic (ROC) curves. Proceedings of the Thirty first Annual SAS Users Group International Conference; 2006; Cary, NC.
21. Gao SP, Mark KG, Leslie K, et al. Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. J Clin Invest. 2007;117(12):3846-3856.
22. Jaganathan S, Yue P, Turkson J. Enhanced sensitivity of pancreatic cancer cells to concurrent inhibition of aberrant signal transducer and activator of transcription 3 and epidermal growth factor receptor or Src. J Pharmacol Exp Ther. 2010;333(2):373-381.
23. Rosenbluh J, Nijhawan D, Cox AG, et al. beta-catenin-driven cancers require a YAP1 transcriptional complex for survival and tumorigenesis. Cell. 2012; 151(7):1457-1473.